{"nctId":"NCT01967940","briefTitle":"Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults","startDateStruct":{"date":"2013-10-25","type":"ACTUAL"},"conditions":["HIV","HIV Infections","Acquired Immunodeficiency Syndrome"],"count":55,"armGroups":[{"label":"Part 1 Sentinel Cohort (TAF)","type":"EXPERIMENTAL","interventionNames":["Drug: TAF","Drug: Current failing ARV regimen"]},{"label":"Part 1 Randomized Cohort (TAF)","type":"EXPERIMENTAL","interventionNames":["Drug: TAF","Drug: Current failing ARV regimen"]},{"label":"Part 1 Randomized Cohort (Placebo)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Current failing ARV regimen"]},{"label":"Part 2 E/C/F/TAF+ATV","type":"EXPERIMENTAL","interventionNames":["Drug: E/C/F/TAF","Drug: ATV"]}],"interventions":[{"name":"TAF","otherNames":["Vemlidy®","GS-7340"]},{"name":"Placebo","otherNames":[]},{"name":"E/C/F/TAF","otherNames":["Genvoya®"]},{"name":"Current failing ARV regimen","otherNames":[]},{"name":"ATV","otherNames":["Reyataz®"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures\n* Currently taking a failing ARV regimen\n* Plasma HIV-1 RNA ≥ 500 copies/mL but ≤ 100,000 copies/mL at screening\n* Normal ECG\n* Estimated glomerular filtration rate (eGFR) ≥ 50 mL/min according to the Cockcroft-Gault formula for creatinine clearance\n* Alanine aminotransferase (AST)/aspartate aminotransferase (AST) ≤ 5 × the upper limit of the normal range (ULN)\n* Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin\n* Adequate hematologic function\n* Serum amylase ≤ 5 × ULN\n* Females may enter the study if it is confirmed that she is:\n\n  * Not pregnant or nursing\n  * Of non-childbearing potential (ie, have had a hysterectomy, both ovaries removed, medically documented ovarian failure, or are postmenopausal women \\> 54 years of age with cessation \\[for ≥ 12 months\\] of previously occurring menses), or\n  * Of childbearing potential and agrees to utilize highly effective contraception methods or be non-heterosexually active or practice sexual abstinence from screening throughout the duration of study treatment and for 30 days following study drug dosing\n\n    * Females who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing.\n* Males must agree to utilize a highly effective method of contraception during heterosexual intercourse or be non-heterosexually active, or practice sexual abstinence from first dose throughout the study period and for 30 days following the last study drug dose.\n* Males must agree to refrain from sperm donation from first dose until at least 30 days after the last study drug dose.\n\nKey Exclusion Criteria:\n\n* A new AIDS-defining condition diagnosed within the 30 days prior to screening\n* Hepatitis B surface antigen (HBsAg) positive\n* Hepatitis C antibody positive (individuals with positive hepatitis C virus (HCV) antibody and without detectable HCV RNA are permitted to enroll)\n* History of integrase inhibitor use\n* Screening or historical genotype reports shows Q151M or T69ins or more than 3 TAMs.\n* Screening or historical genotype report shows resistance to integrase inhibitors\n* Individuals experiencing decompensated cirrhosis\n* Current alcohol or substance use\n* History of malignancy within the past 5 years (prior to screening) or ongoing malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma. Individuals with cutaneous KS are eligible, but must not have received any systemic therapy for KS within 30 days of Part 1, Day 1 and must not be anticipated to require systemic therapy during the study.\n* Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Part 1, Day 1\n* Any other clinical condition or prior therapy that would make the individual unsuitable for the study or unable to comply with dosing requirements\n* Participation in any other clinical trial (including observational trials) without prior approval from the sponsor is prohibited while participating in this trial\n* Receiving ongoing therapy with any disallowed medications, including any drugs not to be used with elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide or known allergies to the excipients of E/C/F/TAF STR\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part 1: Percentage of Participants With Plasma HIV-1 RNA Decreases From Baseline Exceeding 0.5 log10 at Day 10","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.3","spread":null},{"groupId":"OG001","value":"60.7","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Change From Baseline in Plasma log10 HIV-1 RNA (Copies/mL) at Day 10","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.72","spread":"0.574"},{"groupId":"OG001","value":"-0.70","spread":"0.628"},{"groupId":"OG002","value":"-0.04","spread":"0.233"}]}]}]},{"type":"SECONDARY","title":"Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities Through Week 24","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities Through Week 48","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Any Treatment-Emergent Adverse Event Through Week 24","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Any Treatment-Emergent Adverse Event Through Week 48","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Analysis at Week 24","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Analysis at Week 48","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL as Defined by the FDA Snapshot Analysis at Week 24","description":"The percentage of participants with HIV-1 RNA \\< 400 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL as Defined by the FDA Snapshot Analysis at Week 48","description":"The percentage of participants with HIV-1 RNA \\< 400 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2: Change From Baseline in Plasma log10 HIV-1 RNA (Copies/mL) at Week 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.96","spread":"0.754"}]}]}]},{"type":"SECONDARY","title":"Part 2: Change From Baseline in Plasma log10 HIV-1 RNA (Copies/mL) at Week 48","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.04","spread":"0.594"}]}]}]},{"type":"SECONDARY","title":"Part 2: Change From Baseline in CD4+ Cell Count at Week 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":"92.8"}]}]}]},{"type":"SECONDARY","title":"Part 2: Change From Baseline in CD4+ Cell Count at Week 48","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":"109.0"}]}]}]},{"type":"SECONDARY","title":"Part 2: Change From Baseline in CD4+ Percentage at Week 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"2.35"}]}]}]},{"type":"SECONDARY","title":"Part 2: Change From Baseline in CD4+ Percentage at Week 48","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":"2.99"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["Upper respiratory tract infection","Malaria","Neuropathy peripheral","Toothache","Hyperbilirubinaemia"]}}}